Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor (NYSE: AVTR) delivers essential materials and technologies powering breakthroughs in life sciences and advanced industries. This news hub provides investors and professionals with direct access to official announcements, including product innovations, financial results, and strategic partnerships shaping the future of bioprocessing and semiconductor manufacturing.
Track critical updates across Avantor's core operations: earnings disclosures detailing performance in pharmaceutical solutions, regulatory filings impacting global supply chains, and advancements in sustainable production methods like their viral vector processing systems. Discover how developments in brands like J.T. Baker and Macron Fine Chemicals influence research and manufacturing efficiency worldwide.
Our curated news collection serves as a decision-making tool for monitoring Avantor's role in enabling scientific progress across 180+ countries. Bookmark this page for real-time insights into leadership changes, facility expansions, and emerging applications in gene therapy support systems.
Avantor (NYSE: AVTR) on October 30, 2025 launched a next-generation sterile sampling platform and pre-engineered PUPSIT assemblies to streamline bioprocessing qualification and in-process decision-making.
The suite includes NBSS (needle-based), NFSS (needle-free), EVSS (exact-volume sampling) and OmniTop, offering modular multi-sample configurations, closed-path designs, standardized bills of materials, and supplier-agnostic PUPSIT assemblies that integrate with common filtration trains to reduce line breaks, operator intervention, and setup variability.
Avantor says the products support single-use and hybrid facilities across clinical to commercial scale, aiming to improve product protection, operational safety, and speed of decisions.
Avantor (NYSE: AVTR) reported Q3 2025 results for the quarter ended September 30, 2025: net sales $1.62B (down 5.3% YoY), net loss $712M and GAAP diluted loss per share of $1.04, driven by a $785M non-cash goodwill impairment in the Distribution reporting unit.
Adjusted results included Adjusted EBITDA $267.9M, adjusted EPS $0.22, operating cash flow $207.4M, free cash flow $171.7M, and adjusted net leverage of 3.1x. The Board authorized a $500M share repurchase program. A conference call and webcast were scheduled for October 29, 2025 at 8:00 AM ET.
Avantor (NYSE: AVTR) announced a collaboration with p-Chip Corporation on October 23, 2025 to co-develop "Smart Consumables" by embedding p-Chip microtransponder technology into Avantor's laboratory and clinical consumables.
The Smart Consumables (vials, slides, cassettes, tubes, plates) will carry a unique, secure identifier to enable end-to-end traceability, automated digital process control, and compliance with Chain-of-Identity (COI) requirements for life sciences, diagnostics, bio-manufacturing and healthcare workflows, addressing demands from individualized therapies such as cell and gene treatments.
Avantor (NYSE: AVTR) announced a strategic partnership with BlueWhale Bio on Oct 15, 2025 to accelerate CAR-T manufacturing by scaling production of Synecta™ cell-derived nanoparticles (CDNPs).
The collaboration combines Avantor's bioprocessing and GMP manufacturing capabilities with BlueWhale Bio's Synecta CDNP platform, aiming to produce GMP-grade CDNP materials to shorten CAR-T expansion time and increase manufacturing capacity.
BlueWhale Bio data cited earlier cell division, higher cell yields, and fewer process interventions, and notes Synecta T1 CDNPs are used in a 3-day CAR-T clinical trial.
Avantor (NYSE: AVTR) announced a chairman transition: independent director Gregory L. Summe will become Chairman of the Board effective January 1, 2026. Current Chairman Jonathan Peacock will step down as chairman and as a director at the end of 2025 after nearly nine years of service.
Since joining the board in 2020, Mr. Summe has chaired the Nominating and Governance Committee and served on the Compensation Committee. The company referenced its recent CEO change to Emmanuel Ligner and the addition of Greg Lucier to the board as part of its current governance composition.
Avantor (NYSE: AVTR) announced on October 3, 2025 that Gregory T. Lucier has been appointed to its Board of Directors. Mr. Lucier brings more than three decades of life sciences leadership, currently serving as Executive Chairman and CEO of Corza Medical, Chairman of the Board at Dentsply Sirona, and a board member of Maravai LifeSciences. He previously served as Chairman and CEO of NuVasive and Life Technologies. The board and chairman Jonathan Peacock said Lucier’s experience will support Avantor’s focus on driving growth and profitability across its Lab Solutions and Bioscience Production segments and delivering sustainable shareholder value.
Avantor (NYSE:AVTR), a global provider of mission-critical products and services for life sciences and advanced technology industries, will release its Q3 2025 financial results before market open on Wednesday, October 29, 2025.
The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the results. Investors can access the live audio webcast through the Events & Presentations section of Avantor's investor relations website at ir.avantorsciences.com. A replay will be available for 30 days following the presentation.
Avantor (NYSE:AVTR), a global provider of life sciences and advanced technology products, has responded to Engine Capital's letter by reaffirming its commitment to shareholder value creation. The company highlighted several strategic initiatives, including the appointment of Emmanuel Ligner as CEO effective August 18, 2025, the implementation of a $400 million cost transformation program, and successful debt reduction of $1.5 billion over the past 18 months.
The Board emphasized its focus on strengthening growth and profitability in Laboratory Solutions and Bioscience Production segments, while highlighting recent leadership changes and increased business transparency through resegmentation efforts.
Engine Capital LP, owning approximately 3% of Avantor (NYSE:AVTR), has sent a letter to the company's Board of Directors highlighting opportunities to enhance shareholder value. The activist investor criticizes Avantor's underperformance, citing ineffective cost controls and poor capital deployment that have led to significant value destruction.
Engine Capital sees potential for 100% share price appreciation by the end of 2027 through implementing cost discipline, operational improvements, portfolio optimization, and immediate share repurchases. The investor also emphasizes the need for board refreshment with directors experienced in healthcare distribution, capital allocation, and relevant leadership roles.
Avantor (NYSE:AVTR) reported mixed Q2 2025 financial results with net sales of $1.68 billion, showing a 1% decrease year-over-year, while organic revenue remained flat. The company posted net income of $64.7 million, down from $92.9 million in Q2 2024, with diluted EPS of $0.09 and adjusted EPS of $0.24.
The Laboratory Solutions segment saw a 3% decline in net sales to $1.12 billion, while Bioscience Production grew 3% to $561.3 million. The company generated operating cash flow of $154.4 million and free cash flow of $125.4 million, maintaining an adjusted net leverage of 3.2x.
Additionally, Avantor announced a significant leadership change, with Emmanuel Ligner appointed as the new President and CEO, effective August 18, 2025, replacing Michael Stubblefield.
FAQ
What is the current stock price of Avantor (AVTR)?
What is the market cap of Avantor (AVTR)?
